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ABSTRACT1 
We have developed recombinant fragment C based rapid point of care dipstick 
devices to assess tetanus immunization status using plasma or whole blood. The 
devices demonstrated specificity of 0.90 and sensitivity of 0.90 (whole blood) / 
0.94 (plasma) at field sites in Bangladesh and The Gambia when compared to a 
commercial ELISA with the immune cut-off titer set as > 0.1 IU/mL. 
 
Keywords: vaccine, tetanus, dipstick, lateral flow, fragment C  
                                                        
1 Abbreviations 
Global Vaccine Action Plan (GVAP); Diphtheria-tetanus-pertussis (DTP3); 
recombinant Fragment C (rFragC); false negatives (FN); true positives (TP); inter 
quartile range (IQR) 
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Childhood vaccination forestalls an estimated 2 to 3 million deaths annually, 
however preventable diseases like maternal and neonatal tetanus remain a 
health problem in many parts of the world (1). A recent analysis of childhood 
mortality placed the burden of neonatal tetanus at 49,000 in 2013, accounting for 
1.7% of all neonatal deaths (2). Immunization campaigns have been pivotal in 
reducing the incidence of this disease (3). Women of reproductive age are 
routinely given tetanus vaccine as part of prenatal care services and during 
campaigns in high-risk areas, while children receive three doses of diphtheria-
tetanus-pertussis (DTP) vaccine in the first year of life.  Despite progress, the 
goal of the Global Vaccine Action Plan (GVAP) to achieve 90% DTP3 vaccination 
coverage worldwide by 2015 has remained unmet and monitoring of 
immunization at the country level has been recommended by the Strategic 
Advisory Group for GVAP (4). A validated test of immune status that is affordable 
and easy to deploy would assist in monitoring immunization programs and 
identifying populations that are susceptible due to lack of vaccination or due to 
poor vaccine efficacy (5).  
   Indirect ELISA is widely used in clinical settings to detect the presence of 
vaccine-induced anti-tetanus antibodies in either whole blood or plasma. We 
previously validated the use of recombinant Fragment C (rFragC) of the tetanus 
toxin as an alternative antigen to tetanus toxoid in ELISA (7). We have now 
developed dipstick tests using rFragC as a rapid and less expensive alternative 
to the available commercial ELISAs. The new dipstick devices use gold-
conjugated rFragC to bind anti-tetanus antibodies in blood or plasma/serum. 
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These complexes are carried by lateral flow of the assay diluent up the dipstick 
and trapped by immobilized rFragC in the dipstick detection zone to generate a 
red-colored antigen-antibody-antigen sandwich signal when the plasma antibody 
titer is > 0.1 IU/mL. For the plasma dipstick device, 20 L of plasma is mixed into 
580 L of diluent in a tube before introduction of the dipstick to start the lateral 
flow and for the whole blood dipstick device, 40 L of blood is spotted on the 
sample pad before placing the dipstick in 360 L of diluent to start the flow. The 
results are discerned by eye as positive or negative by the visual detection of a 
band after 20 minutes, which may also be quantified using a lateral flow reader if 
required. WHO anti-tetanus IgG standards supplied by NIBSC, UK were used to 
calibrate the device so that a signal could be discerned by eye at > 0.125 IU/mL. 
Whole blood and plasma samples commercially obtained in the USA 
(Bioreclamation IVT, New York, USA) were used to initially optimize device 
performance and assess reproducibility.  
Whole blood and plasma samples obtained at field sites of the 
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) and 
of the Medical Research Council Unit, The Gambia (MRCG) were used to 
validate these devices. In Bangladesh, children (n=104) in an urban slum in 
Dhaka who had been vaccinated with a pentavalent vaccine (EPI-Bangladesh 
combined vaccine: diphtheria, pertussis, tetanus, hepatitis B, Haemophilus 
influenzae type b) as part of a longitudinal icddr,b study of child health (8–10) 
were assessed at 53 and 104 weeks of age. The Gambian cohort comprised 
children (n=174) from villages in the Kiang West region who were aged five or 
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under and had received the pentavalent vaccine administered by MRCG at the 
Keneba rural field station in line with the Gambian EPI schedule (11). Collection 
of blood from a small number of adult males (n=20) belonging to the same 
Gambian rural population was included in our study protocol with the aim of 
obtaining tetanus-vaccine naïve samples for assessing specificity of the 
dipsticks. The studies were approved by the relevant authorities: the Ethical 
Review Committee at icddr,b or The Gambia Government/MRC Joint Ethics 
Committee. A reliance agreement was executed between the reviewing 
committees and the University of Virginia Institutional Review Board.  
Plasma testing: Plasma samples were prepared by centrifugation of whole blood 
in EDTA tubes, and plasma was either assayed immediately or rapidly frozen at -
80oC until use. We first used samples from USA (n=274) and Bangladesh (n=29) 
to assess performance of the plasma device. The dipstick signal (quantified as 
peak height in mV using the ESEQuant reader (Qiagen Inc., USA) or evaluated 
by eye as positive/negative) was compared to the corresponding anti-tetanus titer 
in plasma determined in IU/mL using a standard toxoid-based ELISA (TBS, The 
Binding Site, Birmingham, UK). While titers as low as 0.01 IU/mL could be 
protective an ELISA-derived value >0.16 IU/mL was found to more reliably 
predict protection (13).  WHO considers that a titer of 0.1-0.2 IU/mL correlates 
with protection in a ELISA (14). For our analysis, we considered 0.1 IU/mL to be 
the immune cutoff in the TBS ELISA and assigned a value of 0.01 IU/mL or 10 
IU/mL to samples that fell below or above the range of the standard curve (0.01-
7.0 IU/mL).  The dipstick results showed good correlation of the signal quantified 
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as peak height with log-transformed anti-tetanus titer (Fig. 1A) and yielded a 
Spearman correlation coefficient (rs) of 0.8 and 0.79 with samples from US and 
Bangladesh, respectively.   
We then assessed the devices at both field sites using the visual read-out 
as an indication of immune status (Bangladesh n=29; The Gambia n=194). The 
TBS positive titers at the two sites had median values of 1.23 and 1.49 IU/mL 
respectively.  Although only one Gambian child was non-immune by TBS assay, 
a total of thirteen of the TBS positive samples from both sites tested negative 
with the dipstick device. These false negatives (FN) had a median value of 0.2 
IU/mL at the Bangladesh site (n=3) and 0.54 IU/mL at The Gambia site (n=10) 
(Fig. 1C, D). This apparent discrepancy in FN’s may be due to differences in the 
operation of the test at the two sites; independent confirmation of weak test 
signals was routinely done at icddr,b but was not practical at MRCG.   
Whole blood testing: The dipstick device performance with blood was initially 
assessed for correlation of signal strength with plasma anti-tetanus titers using 
USA samples (n=100) and with freshly collected samples at the Bangladesh site 
(n=104) (Fig. 1B).  Whole-blood dipstick results were then evaluated by eye at 
the two field sites (Bangladeshi Children, n=104; Gambian Children, n=143; 
Gambian Adults, n=20). Nine adults and one child were non-immune by TBS 
ELISA. Possibly due to the operational differences at the two sites described 
above, FNs had median values of 0.3 IU/mL at the Bangladesh site (n=9) and 
0.63 IU/mL at The Gambia site (n=16) (Fig. 1E, F) 
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Figure 1. Performance of tetanus dipstick devices. (A,B). Correlation of plasma and blood device 
signals with TBS IU/mL. The dipstick signals with plasma (A) and blood (B) samples from a USA 
cohort (black dots) or a Bangladeshi cohort (red dots) were quantified in mV using a lateral flow 
reader and the signal peak heights (y-axis) were plotted against anti-tetanus ELISA titers (x-
axis(log)) using Prism 6.0 software (GraphPad Software, San Diego, CA). The Spearman rank 
correlation was used in analysis of the data (A) Plasma: USA (rs=0.8, P<0.0001, N= 274); 
Bangladesh (rs =0.79, P<0.0001, N= 29); (B) Blood: USA (rs =0.67, P<0.0001, N= 100); 
Bangladesh (rs =0.75, P<0.0001, N= 104).  (C-F). Effectiveness of dipstick in discrimination of 
tetanus immune plasma (C,D) and blood (E,F) from cohorts in Bangladesh (C,E) and The Gambia 
(D,F).  Anti-tetanus titers of dipstick negative (false negatives, FN) and positive samples (true 
positives, TP) are plotted and inter quartile range (IQR) shown. The dotted line indicates the cut-off 
for protection at 0.1 IU/mL. (C) Bangladesh plasma: FN (N=3, median=0.207 IU/mL, IQR=0.193-
0.379 IU/mL); TP (N=26, median=1.18 IU/mL, IQR=0.8-5.17 IU/mL) (D) Gambian plasma: FN 
(N=10, median=0.54 IU/mL, IQR=0.22-1.03 IU/mL); TP (N=173, median=1.6 IU/mL, IQR=0.84-3.0 
IU/mL)  (E) Bangladesh blood: FN (N=9, median=0.3 IU/mL, IQR=0.17-0.34 IU/mL); TP (N=94, 
median=1.27 IU/mL, IQR=0.71-3.14 IU/mL) (F) Gambian blood: FN (N=16, median=0.63 IU/mL, 
IQR=0.24-2.14 IU/mL); TP (N=137, median=1.6 IU/mL, IQR=0.87-2.95 IU/mL). 
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We combined the results from visual readout at the two field sites for 
assessing the sensitivity and specificity of the dipsticks with whole blood and with 
plasma as substrates (Table 1).  
 
Table 1.  Operational characteristics and assay performance of dipstick devices 
compared to TBS ELISA results (Bangladeshi and Gambian populations, merged 
data)  
Performance 
characteristics 
Plasma Whole blood 
 
Sensitivity (95%CI) 
 
 
0.94 (0.9-0.97) 
(n=212) 
0.90 (0.87-0.94) 
(n=256) 
Specificity (95% CI) 
 
 
0.90 (0.59-1.00) 
(n=11) 
0.91 (0.59-1.00) 
(n=11) 
Positive Predictive Value 0.99 0.99 
Negative Predictive Value 0.43 0.29 
 
The dipstick devices had a sensitivity >0.9 and positive predictive value of 
0.99 with both plasma and whole blood from >200 tetanus–immune individuals in 
our study cohorts. We were able to identify 11 non-immune individuals; samples 
from 10 of these tested negative with our dipstick devices, yielding a specificity of 
0.9. The low negative predictive value (plasma = 0.43; blood = 0.29) reflects the 
number of FN in our testing as well as the small number of unvaccinated 
individuals in our study cohorts (TN) (15) which is a limitation of the study. Our 
results indicate that these tetanus dipstick devices are well-suited for deployment 
using either plasma or blood in vaccination outreach programs, allowing the 
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identification of non-immune or low titer individuals for whom booster shots are 
recommended (16).  However, as is the case with using indirect ELISA as a 
diagnostic, individuals with anti-tetanus titers lower than 0.1 IU/mL are assessed 
by the dipstick devices to be non-immune although levels as low as 0.01 IU/mL 
are known to be protective. However, our experience has been that vaccinated 
individuals most commonly possess titers >0.1 IU/mL. Nevertheless, these tests 
hold potential for rapid and easy point of care assessment of immunity to tetanus 
particularly in community-based surveys, and would be effective even in 
resource-poor settings using a drop of blood obtained from a heel or finger prick. 
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Highlights 
• Point of care evaluation of vaccine-induced anti-tetanus antibodies 
• No cold chain requirement 
• Two dipsticks optimized either for testing serum or blood  
• The devices were tested at two field sites: icddr,b, Bangladesh and MRC 
Keneba, The Gambia 
• The dipsticks compared favorably with the results from a commercial 
ELISA 
